Nautilus Biotechnology, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Other Events

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

2.02,9.01

5.07

2.02,9.01

1.01,9.01

2.02,9.01

8.01

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Post-effective amendment to a registration statement

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

AH Bio Fund II, L.P.

AH Bio Fund II, L.P.

PERCEPTIVE ADVISORS LLC

AH Bio Fund II, L.P.

NAZEM FARZAD

McIlwain Matthew S

Posard Matthew L.

Epperly Melissa B,

Akinsanya Karen

Andreessen Marc L; HOROWITZ BENJAMIN A; AH Bio Fund II, L.P.; AH Equity Partners LSV II, L.L.C.; AH Equity Partners Bio II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.

AH Bio Fund II, L.P.

Murphy Matthew B.

Patel Sujal M

Patel Sujal M

Patel Sujal M

Weld Gwen E

Sankar Subramanian

Mowry Anna

Mallick Parag

Suzuki Kentaro

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission)

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC